Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 6/20 | 0.41 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18738614 | 0.94 | CTSK (0.42) | SIRT6SIRT1CTSKPAOXDPP8 | |
| SCHEMBL27839515 | 0.84 | PAOX (0.42) | SIRT6SIRT1CTSKPAOXGSR | |
| SCHEMBL16478000 | 0.83 | CTSK (0.54) | SIRT6SIRT1CTSK | |
| SCHEMBL10231080 | 0.81 | CTSK (0.41) | CTSKTRPV1 | |
| SCHEMBL10421632 | 0.81 | GSR (0.38) | SIRT6SIRT1CTSKGSRRNPEP | |
| SCHEMBL13128069 | 0.81 | GSR (0.38) | SIRT6SIRT1CTSKGSRRNPEP | |
| SCHEMBL9495080 | 0.81 | FURIN (0.45) | SIRT6SIRT1CTSKCPB2CA1 | |
| SCHEMBL9495059 | 0.81 | FURIN (0.45) | SIRT6SIRT1CTSKCPB2CA1 | |
| SCHEMBL5971430 | 0.81 | CTSK (0.60) | CTSK | |
| SCHEMBL5971426 | 0.81 | CTSK (0.60) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2490029-A1 | Vancomycin analysis | Université Catholique De Louvain (BE) | 2012-08-22 | — | — | EP | claimed |
| JP-6086695-A | — | — | None | — | — | JP | disclosed |
| EP-4304576-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS AND CONTROLLED RELEASE NAFAMOSTAT AND METHODS OF USE THEREOF | Ensysce Biosciences, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-2349241-B1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | SIGNATURE THERAPEUTICS INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9534014-B2 | Pharmaceutical compositions with attenuated release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | 3I, LP | 2015-10-22 | — | — | US | disclosed |
| US-9040032-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150031635-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | 3I, LP | 2015-01-29 | — | — | US | disclosed |
| US-8802681-B2 | Pharmaceutical compositions with attenuated release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20020052422-A1 | Oral drug delivery compositions and methods | EMISPHERE TECHNOLOGIES, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-0696208-B1 | ORAL DRUG DELIVERY COMPOSITIONS | EMISPHERE TECH INC (US) | 2001-08-22 | — | — | EP | disclosed |
| EP-1077070-A2 | Oral drug delivery compositions | Emisphere Technologies, Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| EP-1025840-A2 | Oral drug compositions and methods | Emisphere Technologies, Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| US-5792451-A | AMINO ACID DERIVATIVES AS CARRIERS FOR SENSITIVE AGENTS SUCH AS BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-08-11 | — | — | US | disclosed |
| US-5766633-A | MODIFIED AMINO ACID CARRIER, BIOACTIVE PEPTIDES | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| EP-0696208-A4 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECH INC (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0696208-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | Emisphere Technologies, Inc. (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994023767-A1 | ORAL DRUG DELIVERY COMPOSITIONS AND METHODS | EMISPHERE TECHNOLOGIES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| JP-H0686695-A | ENZYMATIC DETERMINATION OF BETA-LACTAM ANTIBIOTIC | UCB BIOPROD SA | 1994-03-29 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031635-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | COMT, OPRM1, OPRK1 | SIRT6 3035/4885SIRT1 3367/4885CTSK 197/4885 |
| US-20020052422-A1 | Oral drug delivery compositions and methods | ADM2, PTMS, DNPEP | SIRT6 1099/4885SIRT1 2838/4885CTSK 2467/4885 |
| US-20150297736-A1 | Compositions Comprising Enzyme-Cleavable Opioid Prodrugs and Inhibitors Thereof | ACHE, OPRM1, DNPEP | SIRT6 3071/4885SIRT1 3647/4885CTSK 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.